Induction of hepatic differentiation of mouse bone marrow stromal stem cells by the histone deacetylase inhibitor VPA

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2582-2592

  Chen, Ye ^a   Pan, Ruo Lang ^a   Zhang, Xiao Lei ^a   Shao, Jian Zhong ^a   Xiang, Li Xin ^a   Dong, Xue Jun ^b   Zhang, Guo Rong ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b SHAOXING UNIVERSITY   (China)

Author keywords

Bone marrow stromal stem cells; Differentiation; Epigenetic modification; Hepatocyte; Valproic acid

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; PRIMER DNA; VALPROIC ACID;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; MOUSE; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CELLS, CULTURED; DNA PRIMERS; HISTONE DEACETYLASE INHIBITORS; LIVER; MICE; MICE, INBRED ICR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VALPROIC ACID;

ANIMALIA; MUS;

EID: 72949096347     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00471.x     Document Type: Article

References (29)

1. Gronthos S, Akintoye SO, Wang CY, et al. Bone marrow stromal stem cells for tissue engineering. Periodontol 2000. 2006 41 : 188 195.
2. Bernardo ME, Emons JA, Karperien M, et al. Human mesenchymal stem cells derived from bone marrow display a better chondrogenic differentiation compared with other sources. Connect Tissue Res. 2007 48 : 132 140.
3. Luk JM, Wang PP, Lee CK, et al. Hepatic potential of bone marrow stromal cells: development of in vitro co-culture and intra-portal transplantation models. J Immunol Methods. 2005 305 : 39 47.
4. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 284 : 143 147.
5. Oh SH, Witek RP, Bae SH, et al. Bone marrow-derived hepatic oval cells differentiate into hepatocytes in 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Gastroenterology. 2007 132 : 1077 1087.
6. Chen Y, Dong XJ, Zhang GR, et al. In vitro differentiation of mouse bone marrow stromal stem cells into hepatocytes induced by conditioned culture medium of hepatocytes. J Cell Biochem. 2007 102 : 52 63.
7. Snykers S, Vanhaecke T, Papeleu P, et al. Sequential exposure to cytokines reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-like cells. Toxicol Sci. 2006 94 : 330 341.
8. Lee KD, Kuo TK, Whang-Peng J, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology. 2004 40 : 1275 1284.
9. Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002 109 : 1291 1302. (Pubitemid 34546893)
10. Bedada FB, Gunther S, Kubin T, et al. Differentiation versus plasticity: fixing the fate of undetermined adult stem cells. Cell Cycle. 2006 5 : 223 226.
11. Quesenberry PJ, Dooner G, Colvin G, et al. Stem cell biology and the plasticity polemic. Exp Hematol. 2005 33 : 389 394.
12. Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell. 2004 116 : 639 648.
13. Turhan AG. Plasticity of adult stem cells. Transfus Clin Biol. 2003 10 : 103 108.
14. Horwitz EM. Stem cell plasticity: the growing potential of cellular therapy. Arch Med Res. 2003 34 : 600 606.
15. Chen J, Ghazawi FM, Bakkar W, et al. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer. 2006 5 : 71.
16. Cho HH, Park HT, Kim YJ, et al. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J Cell Biochem. 2005 96 : 533 542.
17. Hsieh J, Nakashima K, Kuwabara T, et al. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci USA. 2004 101 : 16659 16664.
18. Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res. 2002 86 : 41 65.
19. Marchion DC, Bicaku E, Daud AI, et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 65 : 3815 3822.
20. Baki L, Alexis MN. Regulation of tyrosine aminotransferase gene expression by glucocorticoids in quiescent and regenerating liver. Biochem J. 1996 320 : 745 753.
21. Nakayama T, Mutsuga N, Tosato G. FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood. 2007 109 : 1363 1372.
22. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005 16 : 107 137.
23. Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res. 2002 8 : 662 664.
24. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996 271 : 15292 15297.
25. Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 2002 22 : 492 511.
26. Ali J, Mansukhani A, Basilico C. Fibroblast growth factor receptors 1 and 2 are differentially regulated in murine embryonal carcinoma cells and in response to fibroblast growth factor-4. J Cell Physiol. 1995 165 : 438 448.
27. Na L, Wartenberg M, Nau H, et al. Anticonvulsant valproic acid inhibits cardiomyocyte differentiation of embryonic stem cells by increasing intracellular levels of reactive oxygen species. Birth Defects Res A Clin Mol Teratol. 2003 67 : 174 180.
28. De Felice L, Tatarelli C, Mascolo MG, et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 2005 65 : 1505 1513.
29. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev. 2008 34 : 206 222.